Recursion Pharmaceuticals Inc (NASDAQ: RXRX) on Monday, soared 1.51% from the previous trading day, before settling in for the closing price of $6.62. Within the past 52 weeks, RXRX’s price has moved between $4.97 and $15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 132.77%. The company achieved an average annual earnings per share of 1.11%. With a float of $226.81 million, this company’s outstanding shares have now reached $291.36 million.
In terms of profitability, gross margin is -26.05%, operating margin of -824.25%, and the pretax margin is -767.94%.
Recursion Pharmaceuticals Inc (RXRX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Recursion Pharmaceuticals Inc is 22.14%, while institutional ownership is 74.83%. The most recent insider transaction that took place on Oct 09 ’24, was worth 95,374. In this transaction Chief Financial Officer of this company sold 15,000 shares at a rate of $6.36, taking the stock ownership to the 1,450,881 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Chief Financial Officer sold 15,000 for $6.32, making the entire transaction worth $94,756. This insider now owns 1,426,506 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 1.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Recursion Pharmaceuticals Inc (RXRX) is currently performing well based on its current performance indicators. A quick ratio of 6.07 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 4.7 million, which is a drop from its year-to-date volume of 5.81 million. As of the previous 9 days, the stock’s Stochastic %D was 67.56%. Additionally, its Average True Range was 0.38.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 20.34%, which indicates a significant decrease from 57.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.69% in the past 14 days, which was lower than the 73.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.68, while its 200-day Moving Average is $8.85. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $6.85. Second resistance stands at $6.98. The third major resistance level sits at $7.14. If the price goes on to break the first support level at $6.55, it is likely to go to the next support level at $6.39. Should the price break the second support level, the third support level stands at $6.26.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
Market capitalization of the company is 1.96 billion based on 237,664K outstanding shares. Right now, sales total 44,580 K and income totals -328,070 K. The company made 14,420 K in profit during its latest quarter, and -97,540 K in sales during its previous quarter.
